Specifically, prolonged GLP-1RA administration (1–3 years or longer) has been associated with elevated thyroid cancer risk in certain populations [4], while high concentrations of liraglutide (100 nM) have been demonstrated to promote breast cancer progression via the NOX4/ROS/VEGF signaling pathway [18]. Here, NOX4 is linked to breast carcinoma.